Cymabay Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

CymaBay Therapeutics

06/08/2021 21:57

* Cymabay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show a no change in quarterly revenue when it reports
results on August 9 (estimated). 
​* Refinitiv's mean analyst estimate for Cymabay Therapeutics
Inc is for a loss of 27 cents per share. For the same quarter
last year, the company reported a loss of 16 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12​, about 67.3% above​ its last closing
price of $3.93. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.25       -0.24      -0.25     Missed  -2.4
 Dec. 31 2020              -0.20      -0.23     Missed  -14.9
 Sep. 30 2020  -0.17       -0.17      -0.17     Met     -2.4​
 Jun. 30 2020  -0.23       -0.24      -0.16     Beat    33.1
 Mar.          -0.30​      -0.30      -0.19     Beat    36.5​
 31​ 2020​                                              
 Dec. 31 2019  -0.37       -0.39      -0.35     Beat    10​
 Sep. 30 2019  -0.38       -0.37      -0.38     Missed  -3.1
 Jun. 30 2019  -0.36       -0.37      -0.35     Beat    4.5
 This summary was machine generated August 6 at 20:57 GMT.  All
figures in US dollars unless otherwise stated